{"entity":{"id":"pacific-edge","kind":"company","name":"Pacific Edge","aka":[],"tldr":"New Zealand company behind the Cxbladder urine tests for bladder cancer.","summary":"Pacific Edge, based in Dunedin, New Zealand, founded in 2001 and listed as PEB.NZ, is the company behind the Cxbladder urine tests for bladder cancer. The Cxbladder family of urine mRNA tests is used in New Zealand's public health system and in US Veterans Affairs and Kaiser pathways, and contested US Medicare coverage in 2024 and 2025 forced a restructuring. OnCo links it to bladder and urothelial cancer and to the Cxbladder product record. Its story shows how reimbursement decisions, rather than test performance, can determine a diagnostic company's fate, and whether urine tests can safely reduce cystoscopy in surveillance is the clinical question behind it. Cxbladder has its own page.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.pacificedgedx.com"}],"tags":[],"related":[],"cancers":["urothelial"],"sections":["diagnostics"],"technologies":[],"targets":[],"drugs":["cxbladder"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Dunedin","country":"NZ","companyType":"diagnostics","website":"https://www.pacificedgedx.com","ticker":"PEB.NZ","founded":2001,"investors":[],"funding":[]},"route":"/companies/pacific-edge/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"drug":[{"id":"cxbladder","kind":"drug","name":"Cxbladder","route":"/drugs/cxbladder/"}],"technology":[{"id":"urine-bladder-cancer-tests","kind":"technology","name":"Urine tests for bladder cancer (cytology, FISH, RNA and methylation)","route":"/technologies/urine-bladder-cancer-tests/"}]}}